Skip to main content
ADGM
NASDAQ Industrial Applications And Services

Adagio Medical reiterates 'going concern' warning, reports $12.9M cash with runway into Q3 2026

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$0.91
Mkt Cap
$20.878M
52W Low
$0.74
52W High
$2.582
Market data snapshot near publication time

summarizeSummary

Adagio Medical reported a significant cash burn and reiterated its 'going concern' warning, with current cash projected to last only into Q3 2026, despite recent positive clinical news.


check_boxKey Events

  • Reiterated Going Concern Warning

    The company explicitly states that its existing cash and cash equivalents are not sufficient to fund operations for at least 12 months from the report date, raising substantial doubt about its ability to continue as a going concern. This follows a similar warning in the March 27, 2026 10-K filing.

  • Critical Cash Position and Short Runway

    Cash and cash equivalents decreased to $12.9 million as of March 31, 2026, down from $17.1 million on December 31, 2025. The company projects this cash will only fund operations into the third quarter of 2026, indicating a very short liquidity runway.

  • Continued Nil Revenue

    Adagio Medical reported no revenue for the three months ended March 31, 2026, consistent with the prior year, due to a strategic pause in commercial activities in Europe.

  • Substantial Net Loss and Operating Cash Burn

    The company reported a net loss of $7.0 million for Q1 2026 and used $4.1 million in cash from operating activities during the same period. The accumulated deficit has grown to $102.6 million.


auto_awesomeAnalysis

This quarterly report highlights severe liquidity issues for Adagio Medical, reiterating the 'going concern' warning previously disclosed in its 10-K on March 27, 2026. The company's cash and cash equivalents have dwindled to $12.9 million, with a projected runway only into the third quarter of 2026. This rapid cash burn and short liquidity horizon are critical, especially given the continued absence of revenue. While the company recently announced positive clinical and regulatory advancements, these financial results underscore the urgent need for additional capital, which could lead to significant dilution for existing shareholders.

At the time of this filing, ADGM was trading at $0.91 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $20.9M. The 52-week trading range was $0.74 to $2.58. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ADGM - Latest Insights

ADGM
May 12, 2026, 8:05 AM EDT
Filing Type: 10-Q
Importance Score:
9
ADGM
May 12, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
ADGM
May 12, 2026, 8:05 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
ADGM
Apr 30, 2026, 5:05 PM EDT
Filing Type: DEF 14A
Importance Score:
7
ADGM
Apr 27, 2026, 6:03 AM EDT
Filing Type: 8-K
Importance Score:
9
ADGM
Apr 26, 2026, 9:37 AM EDT
Source: Reuters
Importance Score:
9
ADGM
Apr 08, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
ADGM
Mar 27, 2026, 8:48 AM EDT
Filing Type: 424B3
Importance Score:
9
ADGM
Mar 27, 2026, 8:46 AM EDT
Filing Type: 424B3
Importance Score:
9
ADGM
Mar 27, 2026, 8:42 AM EDT
Filing Type: 10-K
Importance Score:
9